Novartis announces outcomes from Phase III IRIDIUM study for asthma
Category: #health  By Pankaj Singh  Date: 2020-09-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novartis announces outcomes from Phase III IRIDIUM study for asthma

Novartis International AG, one of the leading multinational healthcare firms, has reportedly announced outcomes from the crucial Phase III IRIDIUM study of ‘Enerzair Breezhaler’ at ERS( European Respiration Society) International Congress 2020 virtual meet.

Reliable sources cite that high once-daily doses of Enerzair Breezhaler dramatically decrease all moderate-or severe-asthma exacerbation incidence in patients whose asthma is uncontrolled on medium to high dose LABA (Long-acting beta2-agonist)/ ICS (inhaled corticosteroids). 

The analysis also found that the safety profile of Enerzair Breezhaler was compatible with the previous Phase III / IIIb PLATINUM clinical development program.

The study found that a large dose of Enerzair Breezhaler (150/50/160 μg) substantially decreased the annualized risk of mild to serious asthma exacerbations by 21 percent (p=0.026) and extreme exacerbations by 31 percent (p=0.003) in asthma patients not sufficiently managed by current inhaled treatment relative to a standard dose (150/50/80 μg) across 52 weeks.

High-dose Enerzair Breezhaler also decreased the annualized risk of all exacerbations by 14 percent (p=0.132) relative to the medium-dose, although this result was not statistically important. Both doses studied displayed a desirable protection and tolerability profile.

Kenneth Chapman, Professor of Medicine at the University of Toronto, claimed in his comment that this post-hoc study supports the efficacy of high-dose IND / GLY / MF as an important step-up treatment choice to help alleviate asthma exacerbations in patients with uncontrolled asthma. 

For the record, Asthma affects around 358 million people across the globe and could cause a significant health, personal, and financial burden when not effectively controlled. On 7 July 2020, Novartis declared the EC (European Commission) approval of Enerzair Breezhaler for the treatment of asthma in adult patients that are not properly managed with a treatment combination of LABA and a strong dose of ICS. 

Source credit - https://www.novartis.com/news/media-releases/novartis-post-hoc-analysis-shows-high-dose-enerzair-breezhaler-reduces-asthma-exacerbations-versus-medium-dose-complementing-key-pivotal-iridium-study-findings



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Dada Group partners with Ferrero for new snack food retail model
Dada Group partners with Ferrero for new snack food retail model
By Pankaj Singh

The new retail model will help Ferrero improve brand reach to younger online customers in China

Chinese on-demand delivery and retail platform, Dada Group has inked...

Aphena Pharma to complete expansion of Solid Dose Division by April
Aphena Pharma to complete expansion of Solid Dose Division by April
By Pankaj Singh

Aphena Pharma Solutions, a pharmaceutical services provider, has reportedly announced the continuous expansion of its Tennessee-based Solid Dose Division worth $21 million. This division is expected to be completed by ...

Canada-based CloudMD buys CMD to expand medical database
Canada-based CloudMD buys CMD to expand medical database
By Pankaj Singh

CloudMD Software & Services Inc., a virtual medical care solutions provider based in Canada, has reportedly announced that it has completed the acquisition of the Canadian Medical Directory (CMD)- the nation’...